首页> 外文期刊>World Journal of Surgical Oncology >A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population
【24h】

A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population

机译:根据韩国人群的分子亚型比较浸润性小叶癌和乳腺浸润性导管癌患者的临床结局

获取原文
           

摘要

Background To investigate the clinicopathological characteristics and the survival outcomes of invasive lobular carcinoma (ILC) patients compared to invasive ductal carcinoma (IDC) patients according to their molecular subtype. Methods We compared the clinicopathological characteristics, breast cancer-specific survival (BCSS) and overall survival (OS) between patients with IDC (n?=?14,547) and ILC (n?=?528). Results The ILC presented with a larger tumor size, more advanced cancer stage, increased rate of hormonal receptor positivity, human epidermal growth factor 2 (HER2) negativity and mastectomy than the IDC. The ILC patients more frequently presented with the luminal A subtype, whereas the IDC patients more frequently presented with the luminal B, HER2-overexpression, or triple negative subtype. The BCSS and OS were not significantly different between the IDC and ILC for each molecular subtype. Conclusions Similar to IDC patients, molecular subtype should be considered when determining the prognosis and treatment regimen for ILC patients.
机译:背景技术根据浸​​润性小叶癌(IDC)分子亚型,比较浸润性小叶癌(ILC)患者的临床病理特征和生存结果。方法我们比较了IDC(n = 14547)和ILC(n = 528)患者的临床病理特征,乳腺癌特异性生存率(BCSS)和总体生存率(OS)。结果与IDC相比,ILC具有更大的肿瘤大小,更晚期的癌症分期,激素受体阳性率,人类表皮生长因子2(HER2)阴性和乳房切除术。 ILC患者更常出现管腔A亚型,而IDC患者更常出现管腔B,HER2过表达或三阴性。对于每种分子亚型,IDC和ILC之间的BCSS和OS均无显着差异。结论与IDC患者相似,在确定ILC患者的预后和治疗方案时应考虑分子亚型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号